Description
Human CellExp™ VEGFR2/Flk-1/KDR, human recombinant is available at Gentaur for Next week delivery.
Mediates almost all of the known cellular responses to VEGF.
Biomolecule/Target: VEGFR2
Alternates names: KDR, CD309, FLK1, VEGFR, VEGFR2, kinase insert domain receptor
Synonyms: KDR, CD309, FLK1, VEGFR, VEGFR2, kinase insert domain receptor
Background Information: Kinase insert domain receptor (KDR) also known as CD309, FLK1, VEGFR, VEGFR2, and is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF. The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.
Reconstitution Instructions: Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.
NCBI Gene Symbol: VEGFR2
Gene ID: 3791
NCBI Accession: P35968
Additional Information
Size: |
20 μg |
Country of Manufacturing Origin: |
USA |
Country of Animal Origin: |
USA |
Gene Source: |
Human |
Recombinant: |
Yes |
Source: |
HEK293 cells |
Purity by SDS-PAGE: |
≥95% |
Assay: |
SDS-PAGE |
Purity: |
N/A |
Assay 2: |
N/A |
Endotoxin Level: |
<1 EU/μg by LAL method |
Activity (Specifications/test method): |
N/A |
Biological activity: |
Measured by its ability to inhibit the VEGF dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is typically 9-20 ng/ml in the presence of 5 ng/ml rhVEGF165. |
Results: |
Measured by its ability to inhibit the VEGF dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is typically 9-20 ng/ml in the presence of 5 ng/ml rhVEGF165. |
Molecular Weight: |
This protein with 6×his tag at C-terminus, and has a calculated MW of 84.1 kDa. DTT-reduced protein migrates as 100-110 kDa protein due to glycosylation. |
Storage Temperature: |
-20°C |
Shelf Life: |
12 months |
Concentration: |
N/A |
Appearance: |
Lyophilized |
Handling: |
Centrifuge the vial prior to opening. |